BioCentury
ARTICLE | Clinical News

Myrbetriq mirabegron regulatory update

March 18, 2013 7:00 AM UTC

Astellas' Astellas Pharma Canada Inc. subsidiary said Health Canada approved Myrbetriq mirabegron to treat overactive bladder (OAB) with symptoms of urgency, urgency incontinence and urinary frequency...